Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | QPCT | Q16769 | 3/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.30 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502592 | 0.88 | CDK9 (0.33) | CNR2ALDH1A1QPCTALOX5APMAPT | |
| SCHEMBL6497536 | 0.88 | MAPT (0.34) | ALDH1A1MAPTMEN1KMT2ATP53 | |
| SCHEMBL6495100 | 0.84 | MAPT (0.35) | MAPTMEN1KMT2ATP53 | |
| SCHEMBL6492876 | 0.81 | GLP1R (0.34) | ALDH1A1ALOX5APMAPTHTR2CSLC6A4 | |
| SCHEMBL6300779 | 0.80 | P2RX3 (0.38) | ALOX5APMAPTTHRBTP53 | |
| SCHEMBL6299341 | 0.80 | ALOX5AP (0.39) | CNR2ALOX5APMAPTSLC16A3SLC16A1 | |
| SCHEMBL27556288 | 0.78 | WDR5 (0.36) | ALDH1A1QPCTHTR2CSLC6A4SLC16A3 | |
| SCHEMBL6502447 | 0.75 | MAPT (0.38) | ALDH1A1MAPTMEN1KMT2ATP53 | |
| SCHEMBL6301746 | 0.75 | PPARG (0.45) | ALDH1A1MAPTTP53 | |
| SCHEMBL6299634 | 0.75 | MAPT (0.39) | MAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | CNR2 708/4885ALDH1A1 476/4885QPCT 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.